MO-BLUE-YONDER
To improve customer experience and satisfaction, retailers are looking to offer a personalized assortment and easy to navigate display of products in their stores. That’s why Nestlé Purina Petcare, the leading manufacturer of pet care products, has successfully implemented Blue Yonder’s category management solution integrated with 3DVR Solutions’ (3DVRS) 3D virtual reality technology to assist its retail partners with better merchandizing of their store shelfs.
Purina is the No. 1 pet care company in the U.S. It offers more than 20 brands in the U.S., feeding 65 million dogs and 51 million cats annually. Purina provides its retail partners with planograms that design shelfs aimed at merchandizing products to meet customer needs. However, with travel restricted during the COVID-19 lockdowns, it needed an alternate way for its associates to work with its retail partners remotely to replicate critical tasks that would otherwise be performed in front of a physical planogram or in store.
Enter 3DVRS’ innovative Retail Visualisation Suite (RVS) Virtual Reality (VR) Headset solution, which combines planogram data from Blue Yonder with a cutting-edge virtual reality headset provider to deliver a fully interactive, networked avatar-based merchandising solution. This integrated solution brings people from all over the globe into a common unique headset experience in the metaverse where they can plan, present and interact. The integrated solution is now also available to other companies who are looking to solve similar challenges.
Thanks to this integrated solution, Purina has achieved some key benefits:
- Removed the need to be in a physical store to make shelfing decisions by bringing people together in the metaverse, which has in turn reduced environmental impact from less travel and decreased training costs.
- Reduced time to merchandise a shelf via an interactive planogram before moving real product.
- Incorporated true-to-life factors into shelf planning.
- Partner with retailers to enhance the customer journey in store and share global best practices.
“3DVRS’ integration with Blue Yonder delivers flexibility, speed and scale, giving us the ability to effectively deploy across the business. The evolution from virtual reality on the desktop to network avatars in the RVS VR Headset solution has been seamless. We can now hold meetings virtually in the metaverse, interact with layouts, products, and store innovations, allowing us to be right at the cutting edge,” said Gene Feldman, training manager, Purina.
Together, Blue Yonder's category management and 3DVRS’ RVS VR Headset solutions have enabled Purina’s retail partners to make faster, more accurate and localized space allocation decisions to help their customers find the products they need more easily while guaranteeing a better shopping and service experience.
“Purina is a fantastic partner to innovate with as they are always looking to the latest technology to give their business the edge. The challenges they presented pushed technological boundaries. Our integration with Blue Yonder gives us the platform to support large enterprises such as Purina. It’s great to bring new tech to the market that makes a real difference. It’s amazing what we have achieved together already, but I sense there's a lot more to come,” said Nigel Hemer, CEO and founder, 3DVR Solutions.
“Working with 3DVRS has allowed us to bring Blue Yonder’s planograms to life in the metaverse where users can merchandise, analyze, interact, and meet as avatars to design shelfs that meet customers’ needs. This is cutting-edge technology at its finest and Purina was one of the first companies to benefit from it. By creating a culture of innovation and thought leadership throughout the organization, Purina is building a great place to work for both their associates and retail partners,” said Phillip Teschemacher, corporate vice president, Manufacturing - EMEA, Blue Yonder.
Additional Resources:
- Learn more about Blue Yonder's category management solution
- Learn how to achieve smarter Category Management with Blue Yonder
About Nestlé Purina PetCare
Nestlé Purina PetCare creates richer lives for pets and the people who love them. Founded in 1894, Purina has helped dogs and cats live longer, healthier lives by offering scientifically based nutritional innovations.
Purina manufactures some of the world's most trusted and popular pet care products, including Purina Cat Chow, Purina ONE, Pro Plan, Fancy Feast and Tidy Cats. Our more than 8,700 U.S. associates take pride in our trusted pet food, treat and litter brands that feed 51 million dogs and 65 million cats every year. More than 500 Purina scientists, veterinarians, and pet care experts ensure our commitment to unsurpassed quality and nutrition. Purina promotes responsible pet care through our scientific research, our products and our support for pet-related organizations.
Over the past five years, Purina has contributed more than $150 million towards organizations that bring, and keep, people and pets together, as well as those that help our communities and environment thrive. Purina is part of Nestlé, a global leader in Nutrition, Health and Wellness. For more information, visit purina.com or subscribe here to get the latest Purina news.
About 3DVR Solutions
As a global Blue Yonder technology partner for 10 years, 3DVRS leverages Blue Yonder planogram and store CAD data to create highly visual 3D environments, enabling retailers & suppliers to plan, design and respond to rapidly changing market conditions. The unique design of 3DVR’s virtual reality solutions deliver automation, speed and scale without inherent dependencies and costs. 3DVR support Blue Yonder customers around the globe, including those on Microsoft Azure. www.3dvrs.com
About Blue Yonder
Blue Yonder is the world leader in digital supply chain transformations and omni-channel commerce fulfillment. Our end-to-end, cognitive business platform enables retailers, manufacturers and logistics providers to best fulfill customer demand from planning through delivery. With Blue Yonder, you'll unify your data, supply chain and retail commerce operations to unlock new business opportunities and drive automation, control and orchestration to enable more profitable, sustainable business decisions. Blue Yonder - Fulfill your Potential™ blueyonder.com
“Blue Yonder” is a trademark or registered trademark of Blue Yonder Group, Inc. Any trade, product or service name referenced in this document using the name “Blue Yonder” is a trademark and/or property of Blue Yonder Group, Inc. All other company and product names may be trademarks, registered trademarks or service marks of the companies with which they are associated.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230124005378/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom